1. In Vivo
  2. >>Market Access

How To Develop A Patient-First Strategy For CGT Commercialization

A patient centric approach to a complex treatment journey

 
• By Jo Shorthouse

Many new drug commercialization decisions need to happen early in the clinical development of a therapy, and cell and gene treatments are no different. As Amerisource Bergen’s Lung-I Cheng tells In Vivo, creating a patient-first blueprint is the best place to start.  

Patient
• Source: Shutterstock

With welcome scientific breakthroughs catalyzing cell and gene therapy (CGT) development, more companies than ever before are now preparing to commercialize advanced medicinal products. Many firms behind the science of CGTs are emerging biotechs that do not have sales and marketing weight of large pharma. Despite this, the road to CGT market access is not insurmountable for a smaller company; ask the right questions in the planning phases of the clinical design and finding the right patients is a great beginning to a what could be a fruitful journey to the patient.

This coming year, 13 new cell or gene therapies could be approved in the US, Europe or both. 2022 was...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

Wealth Of MedTech Innovator Asia Pacific Entries Underlines Rising Caliber Of Local Technologies

 
• By Ashley Yeo

The culmination of the MedTech Innovator APAC awards program 2025 comes later this month when the top prizes are handed out at the grand final in Singapore. But all cohort companies benefit from the competition’s mentoring process, says awards organizer Fredrik Nyberg.

China’s Policies Prompt Reflection Among Global Medtechs As Local Players Adapt

 
• By Ashley Yeo

Chinese medtechs are expanding rapidly worldwide, but gaining market access within China itself – poised to become the world’s largest medtech market – is proving to be a very different challenge.

Five High Impact Drug Launches Expected In 2026

 
• By Lucie Ellis-Taitt

A new report highlighting 62 key drug launches expected in 2026 includes five products that are predicted to hit a golden trifecta of being a first launch, having practice-changing potential and the promise of being a blockbuster.

US Tariffs And Geopolitical Tensions Push EU To New Trade Routes And Infrastructure Growth

 
• By Francesca Bruce

The EU is diversifying its trading partners, which means that new markets may open up to the pharmaceutical industry, countering transatlantic tensions.

More from In Vivo

Podcast: The Potential Of AI In Developmental Cell Biology

 
• By David Wild

In this episode, In Vivo speaks with Micha Breakstone, co-founder and CEO of Somite.AI, and Samantha Dale Strasser, VP of strategy, to explore how their techbio is applying foundation models to human cell differentiation.

A Year Of Firsts As Biosimilars Build Momentum In US

 
• By Dave Wallace

In a busy year for US biosimilars, 2025 saw more than a dozen approvals as multiple biologics faced competition for the first time – including Stelara. However, concerns persist over the lack of rivals in development for numerous brands coming off-patent, with a hope that regulatory streamlining can

Pharmatech Funding: What Corporate VCs Actually Want

 
• By David Wild

Corporate venture arms can be powerful growth partners, but founders who don’t take time to understand them risk missing their greatest value.